Assessing the role of ADAM10 in Trastuzumab treatment and resistance

<p>Overexpression of the HER2 receptor occurs in about 15-20% of all breast cancers and is correlated with poor prognosis. Trastuzumab (Herceptin®), a monoclonal antibody targeting HER2, was shown to prolong survival of these patients. However, primary or acquired resistance remains a drawback...

Ful tanımlama

Detaylı Bibliyografya
Yazar: Feldinger, K
Diğer Yazarlar: Kong, A
Materyal Türü: Tez
Dil:English
Baskı/Yayın Bilgisi: 2012
Konular:

Benzer Materyaller